Company intelligence / Profile preview

Lotus Tissue Repair

Cambridge, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lotus Tissue Repair developed the first and only protein replacement therapy for dystrophic epidermolysis bullosa (DEB), a severe orphan skin disease caused by mutations in the COL7A1 gene. Their lead candidate was a recombinant form of human collagen type VII intended as an intravenous therapy. The company was acquired by Shire in early 2013 while its lead program was still in preclinical development. No clinical results were reported prior to acquisition[2][5].

Therapeutic areas: Dermatology
Modalities: Protein replacement therapy (recombinant human collagen type VII, rC7)
Industry: Biotech

Drug pipeline

1 asset

rC7

Pre-clinical

Indications: Dystrophic epidermolysis bullosa

Partnerships

DEBRA International and DEBRA of America for patient registry development[2]

Beyond the preview

Go deeper on Lotus Tissue Repair.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lotus Tissue Repair.

Explore the full profile